Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop.

2.50
Hdl Handle:
http://hdl.handle.net/10541/67981
Title:
Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop.
Authors:
Zinzani, Pier Luigi; D'Amore, Francesco; Bombardieri, Emilio; Brammer, Caroline V; Codina, José Gómez; Illidge, Timothy M ( 0000-0003-3191-7324 ) ; Jurczak, Wojciech; Linkesch, Werner; Morschhauser, Franck; Vandenberghe, Elisabeth; Van Hoof, Achiel
Abstract:
Radiolabelled immunotherapy is a significant step forward in the treatment of non-Hodgkin's lymphoma (NHL), with preliminary data suggesting long remissions in some patients. 90Y-ibritumomab tiuxetan is the only therapy approved for use after rituximab failure and is currently indicated in the EU for the treatment of adults with rituximab-relapsed or refractory CD20-positive follicular B-cell NHL. However, retrospective analyses confirm better responses when 90Y-ibritumomab tiuxetan is used earlier in the disease course. An expert panel of oncologists, haematologists and nuclear medicine physicians met at an European workshop to discuss proposed therapeutic algorithms for follicular lymphoma and the preliminary medical evidence supporting the incorporation of 90Y-ibritumomab tiuxetan as an early therapeutic option. Phase II data indicate that 90Y-ibritumomab tiuxetan either alone as primary therapy or as consolidation therapy following induction chemotherapy with or without rituximab achieves high response rates in follicular lymphoma, with complete remission rates of 62-80%. Phase III data are warranted, but based on preliminary observations the expert panel recommended incorporation of radiolabelled immunotherapy into national lymphoma treatment algorithms across Europe. This approach would maximise the therapeutic potential of this agent by encouraging its use early in the disease course of follicular lymphomas.
Affiliation:
Institute of Hematology and Oncology Seràgnoli, Via Massarenti 9, 40138 Bologna, Italy. plzinzo@med.unibo.it
Citation:
Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop. 2008, 44 (3):366-73 Eur. J. Cancer
Journal:
European Journal of Cancer
Issue Date:
Feb-2008
URI:
http://hdl.handle.net/10541/67981
DOI:
10.1016/j.ejca.2007.12.008
PubMed ID:
18194857
Type:
Article
Language:
en
ISSN:
0959-8049
Appears in Collections:
All Paterson Institute for Cancer Research; School of Cancer and Imaging Sciences

Full metadata record

DC FieldValue Language
dc.contributor.authorZinzani, Pier Luigi-
dc.contributor.authorD'Amore, Francesco-
dc.contributor.authorBombardieri, Emilio-
dc.contributor.authorBrammer, Caroline V-
dc.contributor.authorCodina, José Gómez-
dc.contributor.authorIllidge, Timothy M-
dc.contributor.authorJurczak, Wojciech-
dc.contributor.authorLinkesch, Werner-
dc.contributor.authorMorschhauser, Franck-
dc.contributor.authorVandenberghe, Elisabeth-
dc.contributor.authorVan Hoof, Achiel-
dc.date.accessioned2009-05-12T17:58:12Z-
dc.date.available2009-05-12T17:58:12Z-
dc.date.issued2008-02-
dc.identifier.citationConsensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop. 2008, 44 (3):366-73 Eur. J. Canceren
dc.identifier.issn0959-8049-
dc.identifier.pmid18194857-
dc.identifier.doi10.1016/j.ejca.2007.12.008-
dc.identifier.urihttp://hdl.handle.net/10541/67981-
dc.description.abstractRadiolabelled immunotherapy is a significant step forward in the treatment of non-Hodgkin's lymphoma (NHL), with preliminary data suggesting long remissions in some patients. 90Y-ibritumomab tiuxetan is the only therapy approved for use after rituximab failure and is currently indicated in the EU for the treatment of adults with rituximab-relapsed or refractory CD20-positive follicular B-cell NHL. However, retrospective analyses confirm better responses when 90Y-ibritumomab tiuxetan is used earlier in the disease course. An expert panel of oncologists, haematologists and nuclear medicine physicians met at an European workshop to discuss proposed therapeutic algorithms for follicular lymphoma and the preliminary medical evidence supporting the incorporation of 90Y-ibritumomab tiuxetan as an early therapeutic option. Phase II data indicate that 90Y-ibritumomab tiuxetan either alone as primary therapy or as consolidation therapy following induction chemotherapy with or without rituximab achieves high response rates in follicular lymphoma, with complete remission rates of 62-80%. Phase III data are warranted, but based on preliminary observations the expert panel recommended incorporation of radiolabelled immunotherapy into national lymphoma treatment algorithms across Europe. This approach would maximise the therapeutic potential of this agent by encouraging its use early in the disease course of follicular lymphomas.en
dc.language.isoenen
dc.subjectFollicular Lymphomaen
dc.subjectGuidelinesen
dc.subjectImmunotherapyen
dc.subjectNon-Hodgkin's Lymphomaen
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshEurope-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLymphoma, Follicular-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshRadioimmunotherapy-
dc.subject.meshRadiopharmaceuticals-
dc.subject.meshTreatment Outcome-
dc.titleConsensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop.en
dc.typeArticleen
dc.contributor.departmentInstitute of Hematology and Oncology Seràgnoli, Via Massarenti 9, 40138 Bologna, Italy. plzinzo@med.unibo.iten
dc.identifier.journalEuropean Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.